GALT · Galectin Therapeutics Inc
$3.85
-0.16 (-3.88%)
At close · Jul 21
Market Cap
$253.22M
Shares
65.86M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Joel Lewis | CEO | $1,189,674 |
| Khurram Jamil | Chief Medical Officer | $945,847 |
| Jack W. Callicutt | CFO | $716,945 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Joel Lewis | CEO | $963,647 |
| Pol F. Boudes | Former Chief Medical Officer | $770,280 |
| Jack W. Callicutt | CFO | $561,419 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Joel Lewis | CEO | $974,181 |
| Pol F. Boudes | Former Chief Medical Officer | $794,577 |
| Jack W. Callicutt | CFO | $566,564 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Joel Lewis | CEO | $1,167,621 |
| Pol F. Boudes | Former Chief Medical Officer | $923,683 |
| Jack W. Callicutt | CFO | $705,918 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Pol F. Boudes | Former Chief Medical Officer | $1,082,481 |
| Harold H. Shlevin | CEO | $919,336 |
| Joel Lewis | CEO | $753,558 |
| Jack W. Callicutt | CFO | $720,372 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Harold H. Shlevin | CEO | $1,306,507 |
| Jack W. Callicutt | CFO | $778,124 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Harold H. Shlevin | CEO | $1,730,815 |
| Jack W. Callicutt | CFO | $1,266,497 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Jack W. Callicutt | CFO | $406,011 |
| Harold H. Shlevin | CEO | $405,155 |